Cushing's syndrome: drug targets and therapeutic options

Paez-Pereda, M; Arzt, E; Stalla, GK

アイテム詳細

登録内容を編集ファイル形式で保存

一時保存へ追加

タグ情報を表示リリース履歴を表示詳細要約

公開

学術論文

Cushing's syndrome: drug targets and therapeutic options

MPS-Authors

Paez-Pereda, M
Max Planck Institute of Psychiatry, Max Planck Society;

Arzt, E
Max Planck Institute of Psychiatry, Max Planck Society;

Stalla, GK
Max Planck Institute of Psychiatry, Max Planck Society;

External Resource

There are no locators available

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

フルテキスト (公開)

公開されているフルテキストはありません

付随資料 (公開)

There is no public supplementary material available

引用

Paez-Pereda, M., Arzt, E., & Stalla, G. (2002). Cushing's syndrome: drug targets and therapeutic options. Expert Opinion on Therapeutic Patents, 12(10), 1537-1546.

引用: https://hdl.handle.net/11858/00-001M-0000-000E-A141-E

要旨

Cushing''s syndrome is caused by endocrine and metabolic alterations produced by high levels of glucocorticoids. Glucocorticoid excess is usually a result of exogenous administration of glucocorticoids or alteration of the hypothalamus-pituitary-adrenal (HPA) axis. However, in the majority of patients it is due to an adrenocorticotrophic hormone (ACTH)-secreting pituitary adenoma. Other possible causes are ectopic ACTH-secreting tumours of the lung, glucocorticoid-producing adrenal tumours and other ectopic tumours. The symptoms include central fat deposition, altered energy and protein metabolism, hypertension and depression. The molecular mechanisms that regulate the HPA axis provide a rationale to correct the alterations observed in Cushing''s syndrome. Recent developments have identified possible targets and drugs for therapy at different levels of the HPA axis. This article reviews patents claiming novel targets and drugs for Cushing''s syndrome in the period 1997-200